Adenocarcinoma of Lung: all 315 studies
Page 1 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.
- Firmonertinib Plus Chemotherapy for Unresectable EGFR PACC-Mutant Stage III Lung Cancer: A Phase II StudyNot yet recruitingNCT07878871Phase 2
- Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V MutationNot yet recruitingNCT07875920Phase 1
- DBC-664 in Adult Patients With Solid TumorsRecruitingNCT07705035Phase 1
- Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung CancerNot yet recruitingNCT07675876Phase 1
- Deep Learning Time-Series Prediction of Long-Term Growth Patterns of Pulmonary Ground-Glass Nodules Using Serial CTNot yet recruitingNCT07647692
- Ex Vivo Drug Response Profiling and Outcome Prediction in Lung AdenocarcinomaRecruitingNCT07636252
- Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With LorlatinibRecruitingNCT07633626
- CLINICAL STUDY TO IDENTIFY BIOMARKERS FOR TUMOR SPREAD THROUGH AIR SPACES STATUSNot yet recruitingNCT07630246
- Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung AdenocarcinomaRecruitingNCT07624487Phase 2
- Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural EffusionNot yet recruitingNCT07482605Phase 2
- Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain MetastasesRecruitingNCT07481786Phase 3
- Low-glucose/High-fat Intake Dietary Regimen as a Tool for Empowering Diagnostic Accuracy of 2-[18F]FDG PET/CT in Lepidic-predominant Growth Lung AdenocarcinomaRecruitingNCT07479095Not applicable
- Partial Tumor Irradiation and Immunotherapy for Unresectable Lung CancerRecruitingNCT07423169Not applicable
- PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLCRecruitingNCT07416058Phase 2
- Peripheral Blood ETASTs for Predicting Efficacy of Chemoimmunotherapy in NSCLCNot yet recruitingNCT07392073
- Evaluation of Different Sizes of Left-Sided Double-Lumen Tubes for Thoracic Surgery in a Tertiary Level Teaching HospitalNot yet recruitingNCT07373171Not applicable
- SL-28 for Advanced Solid TumoursRecruitingNCT07341737Phase 1/2
- Prediction of Targeted Therapy Efficacy in EGFR-mutant Lung Cancer Patients Using AI-based Multimodal DataNot yet recruitingNCT07287904
- ADH1B and ALDH Gene Variants and Lung Cancer RiskNot yet recruitingNCT07273279
- Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung AdenocarcinomaRecruitingNCT07235280Early Phase 1
- Engagement of Veterans With Lung CancerRecruitingNCT07219251Not applicable
- Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCTNot yet recruitingNCT07169903Phase 3
- MOv19-BBz CAR T Cells in FRa+ CancersRecruitingNCT07116057Phase 1
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsRecruitingNCT07090499Phase 1
- Pleural Effusion Biomarkers in Lung Adenocarcinoma PatientsRecruitingNCT07012759
- Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung AdenocarcinomaNot yet recruitingNCT06918782Phase 2
- Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung AdenocarcinomaNot yet recruitingNCT06858410Phase 3
- Clinical Application of PET Imaging Targeting MSLN in Malignant TumorsRecruitingNCT06843629
- Orlistat Overcoming Third-generation EGFR-TKI ResistanceNot yet recruitingNCT06818955Phase 2
- Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical StudyNot yet recruitingNCT06785584Phase 4
- Lymph Node Pathologic Grading StrategyRecruitingNCT06745830
- Plasma Exosomes Reveal the Efficacy of Targeted Therapy in Patients With EGFR Mutation in Lung AdenocarcinomaEnrolling by invitationNCT06730477
- Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung AdenocarcinomaNot yet recruitingNCT06645743
- Segmentectomy for Solid-dominant Lung CancerRecruitingNCT06634966Phase 3
- TP53 R248Q TCR-T Cell Therapy for Advanced Solid TumorNot yet recruitingNCT06619886Early Phase 1
- Reinforced and Non-Reinforced Staple Lines in Fissureless LobectomyNot yet recruitingNCT06602661Phase 1
- Adjuvant Benmelstobart for Stage IB, Grade 3 Invasive Lung AdenocarcinomaRecruitingNCT06528847Phase 2
- Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
- Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
- Differentiating the Invasiveness of Lung Adenocarcinoma by Dual Energy CT ParameterRecruitingNCT06441357
- Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor MicroenvironmentRecruitingNCT06387134Not applicable
- Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung CancersRecruitingNCT06255197
- Multi-omics Analysis to Characterize the Invasive Evolution of Pulmonary Subsolid NodulesRecruitingNCT06215885
- Pathogenic Variants in Genes Associated With Lung AdenocarcinomaRecruitingNCT06181812
- Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain MetastaticRecruitingNCT06056115Not applicable
- Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)RecruitingNCT06031246Phase 3
- Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)RecruitingNCT06031181Phase 3
- WSI Based DL for Diagnosing the IASLC Grading System of Lung AdenocarcinomaRecruitingNCT05925764
- Early Detection of Lung Cancer With Machine Learning Based on Routine Clinical InvestigationsNot yet recruitingNCT05907577
- Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmRecruitingNCT05838053
- Improving the Intraoperative Diagnosis Accuracy of Invasiveness for Small-sized Lung AdenocarcinomaRecruitingNCT05830812
- Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid TumorsRecruitingNCT05797168Phase 1/2
- Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1016)RecruitingNCT05794724
- Intraoperative Frozen Section Pathology to Guide Surgical Treatment for Lung Adenocarcinoma (ECTOP-1015)RecruitingNCT05794711
- CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid TumorsRecruitingNCT05733000Phase 2
- Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)RecruitingNCT05717803Phase 3
- A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaRecruitingNCT05703516
- Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung CancerRecruitingNCT05665504
- Prognostic Value of Lung Cancer MicroAnatomy in 3DNot yet recruitingNCT05565677
- An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung CancerRecruitingNCT05558904Phase 1/2
- APOLLO 11, Consortium of Italian Centers Involved in Treatment of Patients With Lung Cancer Treated With Innovative Therapies: Real World Data and Translational ReaserchRecruitingNCT05550961
- I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With ImmunotherapyRecruitingNCT05537922
- Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung AdenocarcinomaRecruitingNCT05528458Phase 2
- A Single-arm Exploratory Study of Neoadjuvant TherapyRecruitingNCT05527808Not applicable
- Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary LesionsRecruitingNCT05526573
- Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical ResectionRecruitingNCT05517811
- Neoadjuvant Furmonertinib Plus Bevacizumab or Furmonertinib Monotherapy for Resectable and Potentially Resectable Stage III-IVA EGFR Mutation-Positive Lung AdenocarcinomaRecruitingNCT05503667Phase 2
- AMT-151 in Patients With Selected Advanced Solid TumoursRecruitingNCT05498597Phase 1
- Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid BiopsyRecruitingNCT05469022Phase 2
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaRecruitingNCT05456256Phase 2
- Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALKRecruitingNCT05266846Phase 2
- Primary Tumor Resection With EGFR TKI for Stage IV NSCLCRecruitingNCT05215548Phase 2
- Shared Decision Making in Patients With Lung CancerRecruitingNCT05191485
- Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung AdenocarcinomaNot yet recruitingNCT05132985Phase 2
- Furmonertinib as Perioperation Therapy in Stage IIIA-IIIB (N1-N2) Resectable EGFR Mutated Lung Adenocarcinoma (FRONT)Not yet recruitingNCT04965831Phase 2
- Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cmRecruitingNCT04937283Not applicable
- Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung AdenocarcinomaRecruitingNCT04339218Phase 3
- Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid TumorsRecruitingNCT04119024Phase 1
- RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II TrialRecruitingNCT04105270Phase 2
- Adjuvant Chemotherapy for High Risk Stage I Lung AdenocarcinomaRecruitingNCT03380468Phase 2/3
- Surgery With or Without Chemotherapy for Stage I NSCLC With Micropapillary Component ≥ 20%RecruitingNCT03351842Phase 2
- Targeted Stem Cells Expressing TRAIL as a Therapy for Lung CancerRecruitingNCT03298763Phase 1/2
- Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung CancerRecruitingNCT03199651Not applicable
- Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid TumorsTerminatedNCT05194735Phase 1/2Results posted
- Milademetan in Advanced/Metastatic Solid TumorsTerminatedNCT05012397Phase 2Results posted
- Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung CancerActive, not recruitingNCT04533451Phase 2Results posted
- Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)CompletedNCT04248829Phase 3Results posted
- LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT04027946Phase 2Results posted
- Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)CompletedNCT03845296Phase 2Results posted
- To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung CancerCompletedNCT03676192Phase 3Results posted
- An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the LungTerminatedNCT03371381Phase 1/2Results posted
- Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)CompletedNCT03184571Phase 2Results posted
- A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to ErlotinibCompletedNCT03076164Phase 1/2Results posted
- CAR T Cells in Mesothelin Expressing CancersCompletedNCT03054298Phase 1Results posted
- Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 InhibitorTerminatedNCT03041181Phase 2Results posted
- Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaTerminatedNCT02839681Phase 2Results posted
- Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With OsimertinibCompletedNCT02759835Phase 2Results posted
- Nintedanib and Weekly Docetaxel in Lung AdenocarcinomaCompletedNCT02668393Phase 1Results posted
- Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaTerminatedNCT02513667Phase 2Results posted
- Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR MutationsCompletedNCT02450591Not applicableResults posted